Strategies to Accelerate the Development of Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges for project teams.  In our latest webinar, experts discuss methodologies for evaluating ADC efficacy, resistance, and immunogenicity that address both antibody-specific and payload-specific mechanisms through various multi-dimensional assays.

This webinar offers a comprehensive perspective on strategies and approaches that are crucial for accelerating research focused on antibody-drug conjugates.